newIcon
newIcon
newIcon
Diffuse Intrinsic Pontine Glioma

Clinical Trials for the Newly Diagnosed Child with DIPG


A review of www.clinicaltrials.gov was done on October 20, 2011 to identify which therapeutic trials are currently listed as open for the newly diagnosed child with DIPG. The following is information on the ten (10) listed trials that were listed as accruing patients as well as one vaccine trial that is yet to open. Clinicaltrials.gov seems to be often not be up to date on trial status. If you have interest or questions it might be wise to contact the primary investigator. Contact information is listed at the bottom of each clinical trial site. Most US clinical trials for DIPG can be found with the key word "pontine glioma" but some are still listed under "brainstem glioma".

*Note- many, if not most clinical trials will not allow you to enter a trial if you have already started treatment.

This information was taken from https://dipgregistry.org/clinical-trials/

TITLE PHASE RECRUITMENT CONDITIONS INTERVENTIONS SPONSORS EXPECTED COMPLETION DATE
PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB (IBRANCE (REGISTERED)) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS Phase 1 Recruiting Solid Tumors; Ewing Sarcoma; Rhabdoid Tumor; Rhabdomyosarcoma; Neuroblastoma; Medulloblastoma; Diffuse Intrinsic Pontine Glioma Drug: Palbociclib; Drug: Temozolomide; Drug: Irinotecan Pfizer December 3, 2023
A Phase 1 Safety Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Children and Young Adults With Relapsed Solid Tumors, Including Recurrent Malignant Brain Tumors Phase 1 Recruiting Neoplasms Drug: BXQ-350 Bexion Pharmaceuticals, Inc. November 2020
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Primary CNS Tumors Phase 1 Recruiting Primary Central Nervous System Neoplasm; Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Malignant Glioma; Recurrent Medulloblastoma; Refractory Diffuse Intrinsic Pontine Glioma; Refractory Malignant Glioma; Refractory Medulloblastoma Drug: Savolitinib National Cancer Institute (NCI) December 31, 2020
A Phase 1, Open-Label, Dose Escalation Study of CLR 131 in Children and Adolescents With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors Phase 1 Recruiting Pediatric Solid Tumor; Pediatric Lymphoma; Pediatric Brain Tumor; DIPG; Neuroblastoma; Ewing Sarcoma; Rhabdomyosarcoma; Osteosarcoma Drug: CLR 131 Cellectar Biosciences, Inc. December 2020
Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With GD2-expressing Brain Tumors (GAIL-B) Phase 1 Not yet recruiting Diffuse Intrinsic Pontine Glioma; High Grade Glioma Genetic: (C7R)-GD2.CART cells; Drug: Cyclophosphamide; Drug: Fludarabine Baylor College of Medicine; Texas Children's Hospital; Center for Cell and Gene Therapy, Baylor College of Medicine December 2034
A Target Validation Study of Fimepinostat in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG) Early Phase 1 Recruiting Diffuse Intrinsic Pontine Glioma; Recurrent Anaplastic Astrocytoma; Recurrent Glioblastoma; Recurrent Malignant Glioma; Recurrent Medulloblastoma Drug: Fimepinostat; Procedure: Therapeutic Conventional Surgery Sabine Mueller, MD, PhD; Pacific Pediatric Neuro-Oncology Consortium; Cannonball Kids' Cancer Foundation; Curis, Inc. June 2027
Phase 2 Trial of Indoximod With Chemotherapy and Radiation for Children With Progressive Brain Tumors or Newly Diagnosed DIPG Phase 2 Recruiting Glioblastoma; Medulloblastoma; Ependymoma; Diffuse Intrinsic Pontine Glioma Drug: Indoximod; Radiation: Partial Radiation; Radiation: Full-dose Radiation; Drug: Temozolomide; Drug: Cyclophosphamide; Drug: Etoposide; Drug: Lomustine Theodore S. Johnson; National Cancer Institute (NCI); Augusta University; Emory University October 2, 2026
Immune Modulatory DC Vaccine Against Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma (GBM) Phase 1 Enrolling by invitation Diffuse Intrinsic Pontine Glioma or Glioblastoma Biological: Immunomodulatory DC vaccine to target DIPG and GBM Shenzhen Geno-Immune Medical Institute December 31, 2022
Feasibility Study of Hypofractionated Radiotherapy in the Setting of Recurrent Diffuse Intrinsic Pontine Glioma Not Applicable Enrolling by invitation Recurrent Diffuse Intrinsic Pontine Glioma Radiation: Hypofractionated Radiotherapy University of Cincinnati; Children's Hospital Medical Center, Cincinnati July 31, 2023
The PRiME Study: PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma Phase 1 Recruiting Recurrent Medulloblastoma; Recurrent Brain Tumor, Childhood; Malignant Glioma Drug: PEP-CMV Gary Archer Ph.D. June 2022
A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients With Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma Phase 1; Phase 2 Recruiting Relapsed Solid Tumor; Refractory Solid Tumor; Relapsed Central Nervous System Tumor; Refractory Central Nervous System Tumor; Diffuse Intrinsic Pontine Glioma; High Grade Glioma Drug: REGN2810 (monotherapy); Drug: REGN2810 (maintenance); Radiation: Conventional or hypofractionated; Radiation: Re-irradiation Regeneron Pharmaceuticals October 2, 2024
International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013) Phase 3 Recruiting Glioblastoma WHO Grade IV; Diffuse Midline Glioma Histone 3 K27M WHO Grade IV; Anaplastic Astrocytoma WHO Grade III; Diffuse Intrinsic Pontine Glioma; Gliomatosis Cerebri Drug: Temozolomide + Valproic Acid; Drug: Temozolomide + Chloroquine University of Göttingen June 1, 2023
A Phase 2 Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas Harboring H3.3 or H3.1 K27M Mutation Phase 2 Recruiting Glioma; Diffuse Intrinsic Pontine Glioma Drug: Panobinostat; Drug: Everolimus University of Michigan Cancer Center September 2025
Phase I Study of GDC-0084, a Brain-Penetrant PI3 Kinase/mTOR Inhibitor, in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas After Radiation Therapy Phase 1 Recruiting Brain and Central Nervous System Tumors Drug: GDC-0084; Radiation: radiation therapy St. Jude Children's Research Hospital June 2024
Phase 2 Randomized Study of RT and Reirradiation at Relapse vs Multiple Elective RT Courses With Same Concomitant CT for Newly Diagnosed Phase 2 Recruiting Diffuse Intrinsic Pontine Glioma Drug: Nimotuzumab; Drug: Vinorelbine; Other: Radiotherapy Fondazione IRCCS Istituto Nazionale dei Tumori, Milano November 2, 2024
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma Phase 1 Recruiting High Grade Glioma, Diffuse Intrinsic Pontine Glioma Drug: PTC596 Children's Hospital Medical Center, Cincinnati July 1, 2027
Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children With High Grade Brain Tumors and Their Caregivers Not Applicable Recruiting Gliomas; Glioblastomas; Astrocytoma; Brain Neoplasm; Brain Cancer Behavioral: Enhanced Mindfulness Intervention; Behavioral: Psychoeducation National Cancer Institute (NCI) April 1, 2020
Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (BRAVO) Phase 1 Recruiting Diffuse Intrinsic Pontine Glioma (DIPG) Biological: TTRNA-DC vaccines with GM-CSF; Biological: TTRNA-xALT; Drug: Cyclophosphamide + Fludarabine Lymphodepletive Conditioning; Drug: Dose-Intensified TMZ; Drug: Td vaccine; Biological: Autologous Hematopoietic Stem Cells (HSC) University of Florida June 2022
MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma (PNOC015) Phase 1; Phase2 Recruting Diffuse Intrinsic Pontine Glioma Drug: Panobinostat Nanoparticle Formulation MTX110; Drug: Convection-Enhanced Delivery (CED) Sabine Mueller, MD, PhD September 1, 2020
A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors Phase 1 Recruiting Central Nervous System Embryonal Tumor, Not Otherwise Specified; Malignant Glioma;Recurrent Atypical Teratoid/Rhabdoid Tumor; Recurrent Childhood Ependymoma; Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Medulloblastoma; Refractory Diffuse Intrinsic Pontine Glioma Drug: Everolimus; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Ribociclib Pediatric Brain Tumor Consortium July 31, 2020
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma Phase 1 Recruiting Glioblastoma Multiforme; High-grade Astrocytoma NOS; CNS Primary Tumor, Nos; Ependymoma, NOS; Diffuse Intrinsic Pontine Gliomas (DIPG); Medulloblastoma Biological: APX005M treatment for recurrent or refractory primary malignant CNS tumor patients; Biological: APX005M treatment for newly diagnosed DIPG patients Pediatric Brain Tumor Consortium; St. Jude Children's Research Hospital;American Lebanese Syrian Associated Charities; The Cancer Therapy Evaluation Program of the National Cancer Institute; Apexigen, Inc.; Solving Kids’ Cancer; Ty Louis Campbell Foundation; A Kids Brain Tumor Cure September 30, 2022
A Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors Phase 2 Active, not recruiting Central Nervous System Neoplasms; Medulloblastoma Drug: Pomalidomide Celgene March 18, 2023
A Phase I Trial of Indoximod and Temozolomide-Based Therapy for Children With Progressive Primary Brain Tumors Phase 1 Recruiting Glioblastoma Multiforme; Glioma; Gliosarcoma; Malignant Brain Tumor; Ependymoma; Medulloblastoma; Diffuse Intrinsic Pontine Glioma; Primary CNS Tumor Drug: Indoximod; Drug: Temozolomide; Radiation: Conformal Radiation; Drug: Cyclophosphamide; Drug: Etoposide NewLink Genetics Corporation December 2019
An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors Observational Recruiting Diffuse Intrinsic Pontine Glioma; PNET; Ependymoma; Germinoma; Medulloblastoma National Cancer Institute (NCI)
ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas Phase 1 Recruiting Diffuse Intrinsic Pontine Glioma; Glioma, Malignant Drug: ONC201 Oncoceutics, Inc. July 24, 2020
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors or DIPG Phase 1 Active, Not Recruiting Pediatric Brain Tumor; Diffuse Intrinsic Pontine Glioma Biological: Ad-RTS-hIL-12; Drug: oral veledimex Ziopharm March 2021
Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring PDGFR/FGFR Alterations Phase 2 Recruiting Glioma Drug: Dasatinib Drug: Everolimus University of Michigan Cancer Center December 1, 2025
A Phase I Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) Phase 1 Recruiting Diffuse Intrinsic Pontine Glioma Malignant Glioma of Brain High Grade Glioma Bithalamic High Grade Glioma Brainstem Glioma Glioblastoma Anaplastic Astrocytoma Drug: Ribociclib Drug: Everolimus Children's Hospital Medical Center, Cincinnati Novartis January 1, 2022
A Phase I and Early Efficacy Study of Convection Enhanced Delivery of Irinotecan Liposome Injection Using Real Time Imaging With Gadolinium in Children With Diffuse Intrinsic Pontine Glioma Phase 1 Recruiting Diffuse Intrinsic Pontine Glioma Drug: Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI) University of California, San Francisco The V Foundation for Cancer Research Pacific Pediatric Neuro-Oncology Consortium June 2020
A Pilot Trial Testing the Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan in Children With Newly Diagnosed DIPG N/A Active, not recruiting Diffuse Intrinsic Pontine Glioma (DIPG) Other: Specialized tumor board recommendation Radiation: Standard radiation therapy University of California, San Francisco Translational Genomics Research Institute May 2020
International Diffuse Intrinsic Pontine Glioma (DIPG) Registry and Repository Observational Recruiting Diffuse Intrinsic Pontine Glioma Cincinnati Children's Hospital Medical Center June 2037
Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy Phase I Recruiting Brain Cancer|Brain Stem Glioma Radiation: Radioactive iodine-labeled monoclonal antibody 8H9 Memorial Sloan-Kettering Cancer Center|Weill Medical College of Cornell University|Johns Hopkins University December 2018
An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908) Phase 2 Recruiting Diffuse Intrinsic Pontine Glioma (DIPG) Biological: Nivolumab Biological: Ipilimumab Bristol-Myers Squibb June 14, 2021
PNOC 007: H3.3K27M Peptide Vaccine for Children With Newly Diagnosed DIPG and Other Gliomas Phase 1 Recruiting Diffuse Intrinsic Pontine Glioma, Glioma Biological: K27M peptide University of California, San Francisco; The V Foundation for Cancer Research; Pacific Pediatric Neuro-Oncology Consortium November 2020
Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma Early Phase 1 Recruiting Diffuse Intrinsic Pontine Glioma Drug: Gemcitabine University of Colorado, Denver December 2019
Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas Phase 1 Recruiting Brainstem Glioma Biological: DNX-2401 Clinica Universidad de Navarra, Universidad de Navarra December 30, 2019
ADVL1217: WEE1 Inhibitor AZD1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Phase 1 Recruiting Diffuse Intrinsic Pontine Glioma Untreated Childhood Anaplastic Astrocytoma Untreated Childhood Anaplastic Oligoastrocytoma Untreated Childhood Glioblastoma Untreated Childhood Gliosarcoma Drug: WEE1 Inhibitor AZD1775 National Cancer Institute (NCI) October 2021
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (BIOMEDE) Phase 2 Recruiting Diffuse Intrinsic Pontine Glioma Drug: Erlotinib Drug: Everolimus Drug: Dasatinib Gustave Roussy, Cancer Campus, Grand Paris; Innovative Therapies For Children with Cancer Consortium October 2018
Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) Phase 1 Phase 2 Active, not recruiting High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Bithalamic High Grade Glioma Drug: Ribociclib Cincinnati Children's Hospital Medical Center January 2018
PNOC 009: CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With DIPG Phase 1 Recruiting Diffuse Intrinsic Pontine Glioma Drug: Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan University of California, San Francisco September 2021
PBTC-047 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma Phase 1 Recruiting Glioma Drug: LBH589 (Panobinostat) Pediatric Brain Tumor Consortium October 1, 2019
Pediatric MATCH Phase 2 Recruiting Malignant Glioma, Recurrent Central Nervous System Neoplasm, Recurrent Glioma Drug options: Ensartinib, Larotrectinib, Olaparib,pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 PI3K/mTOR Inhibitor LY3023414,Selumetinib Sulfate, Tazemetostat, Vemurafenib National Cancer Institute (NCI) December 31, 2021
Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 Phase 1 Phase 2 Recruiting Glioblastoma Multiforme Fibrillary Astrocytoma of Brain Glioma of Brainstem Anaplastic Astrocytoma Pilomyxoid Astrocytoma Mixed Oligodendroglioma-Astrocytoma Brain Stem Glioma Diffuse Intrinsic Pontine Glioma Erbitux and Bevacizumab Weill Medical College of Cornell University January 2018
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, or Hypermutated Brain Tumors Phase 1 Recruiting Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Diffuse Intrinsic Pontine Glioma, Refractory Brain Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma Biological: Pembrolizumab National Cancer Institute (NCI) April 1, 2020
Re-Irradiation of Progressive or Recurrent DIPG N/A Recruiting Recurrent or Progressive Diffuse Intrinsic Pontine Glioma Radiation: re-irradiation University of Calgary October 2021
GSK MEK116540: Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations Phase 1 Recruiting Solid including primary brain tumors and DIPGs Drug: Trametinib, Drug: Dabrafenib GlaxoSmithKline October 2020
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma Phase 1 Recruiting Diffuse Intrinsic Pontine Glioma Other: Laboratory Biomarker Analysis Drug: Vorinostat Radiation: Radiation Therapy Drug: Temsirolimus M.D. Anderson Cancer Center October 31, 2020
Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma Phase 2 Recruiting Glioblastoma (GBM); DIPG Drug: Doxorubicin Meyer Children's Hospital July 2020
Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines Phase 1 Active, not recruiting Diffuse Intrinsic Pontine Glioma Biological: Autologous dendritic cells Fundació Sant Joan de Déu; Institut d'Investigacions Biomèdiques August Pi i Sunyer March 2019
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Phase 1 Phase 2 Recruiting Pilomyxoid Astrocytoma Pilocytic Astrocytoma Glioma, Astrocytic Optic Nerve Glioma Pleomorphic Xanthoastrocytoma Glioblastoma Multiforme Anaplastic Astrocytoma Gliosarcoma Diffuse Intrinsic Pontine Glioma DIPG Low-grade Glioma Brainstem Glioma Drug: Mebendazole Drug: Vincristine Drug: Carboplatin Drug: Temozolomide Drug: Bevacizumab Drug: Irinotecan Mark Atlas; Janssen Pharmaceuticals; Northwell Health April 2020
Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Phase 1 Recruiting Diffuse Intrinsic Pontine Glioma Brain Tumor, Recurrent Solid Tumor, Recurrent Neuroblastoma, Recurrent, Refractory Ewing Sarcoma, Recurrent, Refractory Rhabdomyosarcoma, Recurrent, Refractory Osteosarcoma, Recurrent, Refractory Rhabdoid Tumor, Recurrent, Refractory Drug: Abemaciclib Children's Healthcare of Atlanta/Emory University October 2018
Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Recurrent or Refractory Brain Tumors Phase 1 Active, Not Recruiting Astrocytoma Childhood Atypical Teratoid/Rhabdoid Tumor Diffuse Intrinsic Pontine Glioma Glioma Recurrent Childhood Anaplastic Oligodendroglioma Recurrent Childhood Brain Neoplasm Recurrent Childhood Glioblastoma Recurrent Childhood Medulloblastoma Recurrent Primitive Neuroectodermal Tumor Refractory Brain Neoplasm Biological: Sargramostim Biological: Wild-type Reovirus Mayo Clinic April 2020
Molecular Analysis of Samples from Patients with Diffuse Intrinsic Pontine Glioma and Brainstem Glioma Observational Recruiting Diffuse Intrinsic Pontine Glioma|Brainstem Glioma Not applicable Children's Research Institute April 2


Finding Clinical Trials


The good news is that parents can search for clinical trials themselves.  From the synopsis of the trial, parents can review the inclusion/exclusion criteria, find where the trial is being offered and contact information of the investigators.  For completed studies, publications citations are included.

The bad news is that there is no one place to easily search for clinical trials.   Each site has its own advantages and disadvantages.  Here are some of the most useful sites...

Clincaltrials.gov is service of the NIH which registers federally and privately supported clinical trials in the US and around the world. There are over 56,000 trial listings including 155 countries.   One of the greatest advantages is that the site is the ability to search by keywords.   Examples of keywords include pontine glioma, brainstem glioma, intrinsic glioma and recurrent solid tumor.   For more detailed help on basic and advanced searches - Help for Searching ClinicalTrials.gov

The National Cancer Institute has a listing of over 6,000 clinical trials.  One of the features allows one to search specifically for trials under brain tumor, child, brainstem glioma.   One can also search location through a zip code.

The primary objective of the Pediatric Brain Tumor Consortium is to rapidly conduct phase 1 and 2 clinical evaluations of new therapeutic drugs, intrathecal agents, delivery technologies, biological therapies, and radiation treatment strategies in children through 21 years of age with primary CNS tumors. The PBTC includes nine leading academic institutions with extensive experience in the design and management of childhood cancer clinical trials for children with brain tumors. Another objective of the PBTC is to develop and coordinate innovative neuroimaging techniques on a consortium-wide basis.  Open and closed protocols are listed on this table.  PI (primary investigator) contact information and a parent summary are available for enrolling studies.

VirtualTrials.com is a private brain tumor site run through The Musella Foundation.  Chose the top button to find a drop down menu to ‘Find a Treatment’.  Two other very helpful pages on this site are:

The doctor/hospital address book

Brain Tumor Center (centers that do more than 50 brain tumors a year and some will provide free reviews of MRIs)

Often individual hospital will have listing of clinical trials that are going on at their institution.  You can search specific hospitals for this information as well.



Understanding Clinical Trials


The Clinical Trial Process by Larry Kun MD for the Pediatric Brain Tumor Foundation of the US defines and examines the clinical trials process, providing parents with a basic understanding of the steps involved in participating in a clinical trial.

Educational Materials About Clinical Trials
This site contains multiple informational articles on various aspects of clinical trials.

This information was taken from http://www.justonemoreday.org/TreatingPontineGliomas/ClinicalTrials.html